Buy Biocon, target price Rs 365: JM Financial
-
almost 2 years ago
Given the multiple near-term levers, enviable biosimilars pipeline, strengthening of leadership teams, favourable valuation and marquee investors backing, JM strongly believes the company is well poised to turn the tide in its favour.
Economic Times